This randomized trial tests whether the addition of chemohormonal therapy improves
PSA-progression free survival in patients with high risk, clinically-localized prostate
cancer. The neoadjuvant approach is taken since there appears to be a higher acceptance
rate in the prostate population for this type of therapy and several phase II trials have
demonstrated its safety. Multiple chemotherapeutic therapies have shown efficacy in
advanced prostate cancer and docetaxel has become the community standard. Many high risk
patients are initiated on LHRH agonists at or near the time of diagnosis of their
prostate cancer. In order to allow the inclusion of these patients in the protocol,
enhanced enrollment and maintain compliance with therapy, up to 3 months of androgen
deprivation therapy prior to enrollment will be permitted. This study will therefore be
able to test the hypothesis that targeting both androgen-sensitive and chemotherapy-
sensitive prostate cancer cells will improve outcomes in these high-risk patients.
OUTLINE: This is a multicenter, randomized study. Patients are stratified according to
nomogram-predicted biochemical progression-free survival at 5 years (0-20.9% vs 21-39.9%
vs 40-59.9% vs ≥ 60%) and androgen-deprivation therapy prior to randomization ≤ 4 months
(no vs yes). Patients are randomized to 1 of 2 treatment arms. Please see the Arms
sections for more details.
The primary and secondary objectives are described below.
Primary:
- To determine whether treatment with neoadjuvant docetaxel and androgen deprivation
therapy prior to radical prostatectomy will increase the rate of 3-year biochemical
progression-free survival (bPFS) compared to treatment with immediate radical
prostatectomy alone for high-risk prostate cancer patients.
Secondary:
- To compare the 5-year bPFS rate, bPFS, disease progression, disease-free survival,
and overall survival of patients randomized to the two arms of this trial
- To determine the safety and tolerability of neoadjuvant docetaxel and androgen
deprivation therapy prior to surgery for high-risk patients undergoing radical
prostatectomy
- To compare the impact of neoadjuvant docetaxel and androgen deprivation therapy on
time to clinically apparent local disease recurrence and metastatic disease in
high-risk patients undergoing radical prostatectomy for clinically localized
prostate cancer
- To compare the impact of neoadjuvant docetaxel and androgen deprivation therapy
relative to RP on pathologic tumor stage, frequency of lymph node metastases and
positive margin rates for high-risk patients undergoing radical prostatectomy for
clinically localized prostate cancer
- To determine if changes in serum testosterone levels will predict bPFS
- To determine prospectively whether PSA doubling time (PSADT) is a surrogate endpoint
for time to clinical metastases and overall survival
Patients are followed up to 15 years post-randomization.
